This is a pretty brutal assessment of Ridaforolimus if you ask me. The JEFFCO analyst is essentially saying that the whole of the company currently is being valued on Ponatinib, lol.
~6 weeks PFS? If that's the case, good luck with Rida in Sarcoma.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.